| Similar Articles |
|---|
 |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development.   |
The Motley Fool
May 8, 2010 |
Sequenom Restarting Development of Diagnostic Test for Down Syndrome The latest news at the San Diego-based biotech. |
The Motley Fool
September 18, 2009
Brian Orelli |
Hey, Sequenom, That's Great, But ... Investors are still waiting for some real second-quarter news from Sequenom. |
The Motley Fool
September 6, 2007
Ryan Fuhrmann |
Jackson Hewitt's Future, by the Numbers Despite some near-term challenges, the company has some lofty long-term goals for growth. Investors, take note. |
The Motley Fool
September 30, 2009
Brian Orelli |
Call Me a Wimp, but I'm Still Nervous Can the mud Sequenom seems to be running in turn to quicksand? |
The Motley Fool
April 30, 2009
Brian Orelli |
How to Lose 75% of Your Company's Value Overnight Sequenom's shares sink 75% after the company said that four employees have been suspended because of "employee mishandling of R&D test data and results" for its revolutionary blood test for Down syndrome. |
The Motley Fool
July 12, 2011
Brian Orelli |
Ducks in Order; Now Let's See Some Data Sequenom is getting all its ducks in a row in preparation for launching its SensiGene Trisomy 21 laboratory-developed test. |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
January 30, 2009
Brian Orelli |
Sequenom Is a Rule Breaker Sequenom has potential; it wants to become the go-to place for molecular diagnostics. |
The Motley Fool
February 23, 2011
Morgan Housel |
A Glimpse of Market Panic The VIX goes boom. |
The Motley Fool
June 6, 2006
Rich Smith |
Foolish Forecast: H&R's Reality Block With the books finally closed on fiscal fourth-quarter, the nation's leading paid tax preparer, H&R Block, reports on the tax season (and full fiscal year) that was tomorrow. Want to know what Wall Street expects to see? Want to know what really matters? |
The Motley Fool
September 24, 2008
Brian Orelli |
100% Results From Sequenom The company presents more data on its molecular diagnostic and buys a lab to run the tests in. |
The Motley Fool
June 15, 2006
Ryan Fuhrmann |
Jackson Hewitt Worth a Look Hewitt trades at a forward P/E multiple 13.3, while H&R is trading at 11.1 times next year's expected earnings. Overall, you don't have to pay that much more for a company with a more favorable growth outlook. |
The Motley Fool
March 1, 2006
Rick Aristotle Munarriz |
Look, Ma, No Tax Blunder Tax prep specialist Jackson Hewitt puts out a clean and solid quarterly report. Investors, take note. |
The Motley Fool
November 30, 2010
Brian Orelli |
Better Buy: Exact Sciences or Sequenom? A battle of the diagnostic test makers. |
The Motley Fool
December 20, 2011
Brian Orelli |
What's Up With the Back-Slapping, Sequenom? Some sales numbers would be nice. |
The Motley Fool
May 25, 2005
Tim Beyers |
Nothing Happened. Buy TiVo! A favorable analyst report sends TiVo shares higher by nearly 20%. If you bought yesterday, good luck. You're probably going to need it. |
The Motley Fool
October 18, 2011
Brian Orelli |
How Not to Gain 75% of Your Company's Value Overnight A 75% increase in price certainly seems possible, but not until investors are convinced that Sequenom can execute on its sales plan the way it has on its clinical plan. |
The Motley Fool
June 27, 2008
Brian Orelli |
The Right Time to Raise Capital After seeing its stock double in less than a month, thanks to some stellar preliminary results from its prenatal Down syndrome test, diagnostic-test maker Sequenom figured now was a perfect time to get some money into the coffers. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
October 3, 2008
Dan Caplinger |
Are Options Your Only Hope? With share values falling through the floor, some investors have turned to the options market for protection from further declines. But there's a catch. |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
The Motley Fool
January 6, 2012
Austin Smith |
What Will the Markets Do Today? A look back and a look forward before the market opens today. |
